8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen (U-PGx)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and ...
Voir le projet
16
Participants partenaires
TERMINÉ
Early risk detection and prevention in ageing people by self-administered ICT-supported assessment and a behavioural change intervention delivered by use of smartphones and smartwatches (PreventIT)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
Lifestyle, disease and biology put older people at risk of functional decline, leading to falls, cognitive impairment, frailty, and negative consequences for quality of life. PreventIT will develop and test an ICT based mHealth System (iPAS) for the consumer market that 1) enables early identification of risk of age-related functional decline, and 2) engenders behavioural change in younger older a ...
Voir le projet
10
Participants partenaires
TERMINÉ
The influence of environmental factors on antimicrobial activity of human intestinal defensins (Defensinactivity)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2018,
Human epithelia are permanently challenged by microorganisms. In the gut, the fraction of strict anaerobic bacteria increases from proximal to distal, reaching 99% of bacterial species in the colon. Moreover, microbial metabolism causes a reduction of the environment to a low redox potential of only –200 mV to –300 mV. Defensins, characterised by three intramolecular disulfide-bridges, are key eff ...
Voir le projet
2
Participants partenaires
TERMINÉ
New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours (PREDECT)
Date du début: 1 févr. 2011, Date de fin: 30 avr. 2016,
Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel th ...
Voir le projet
23
Participants partenaires
TERMINÉ
Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia (NEUROSIS)
Date du début: 1 mars 2009, Date de fin: 31 août 2015,
HYPOTHESIS: Early inhalation of Budesonide (BS) reduces the absolute risk of developing bronchopulmonary dysplasia (BPD) or death in preterm infants born between 23 and 27 weeks gestational age (GA) by 10%. PRIMARY OBJECTIVE: Survival without BPD at 36 weeks GA. SECONDARY OBJECTIVES: (1) neurodevelopment at a corrected age of 18-22 months; (2) adverse treatment effects; (3) mortality at 36 weeks G ...
Voir le projet
15
Participants partenaires
TERMINÉ
Priorities and Standards in Pharmacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy (FightingDrugFailure)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,
Pharmacogenomics is the scientific discipline that relates inter-individual variation in drug response to genetic variation. While there have been major advances in basic genomic knowledge and genotyping technologies, translation into clinical practice has been slow. It is essential we quicken the pace of translational research in pharmacogenomics - at present, we cannot define which patients are ...
Voir le projet
7
Participants partenaires
TERMINÉ
The effects of antibiotic administration on the emergence and persistence of antibiotic-resistant bacteria in humans and on the composition of the indigenous microbiotas at various body sites (antiresdev)
Date du début: 1 nov. 2009, Date de fin: 30 avr. 2013,
The objective of the HEALTH-2009-2.3.1-2 call is to study the impact of different antibiotics on the prevalence of resistant bacteria in the human host. In ANTIRESDEV we will achieve this objective using the approaches suggested in the call as follows. We will use culture-based and culture-independent approaches to investigate the impact of four different types of antibiotics (with different modes ...
Voir le projet
12
Participants partenaires
TERMINÉ
Novel anti-inflammatory compounds for autoimmune diseases (KINACEPT)
Date du début: 1 déc. 2008, Date de fin: 30 nov. 2010,
"The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition ...
Voir le projet